bucladesine has been researched along with Parkinson Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amar, M; Brunelle, A; Debortoli, L; Ferrié, L; Figadère, B; Kadar, H; Latini, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Schmidt, F; Séon-Méniel, B; Touboul, D | 1 |
| Amar, M; Ferrié, L; Figadère, B; Harfouche, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Séon-Méniel, B; Sepulveda-Diaz, JE | 1 |
| Liu, S; Shen, L; Tian, ZM; Wang, RM; Wieman, J; Yan, Y; Yin, F; Zhao, QJ | 1 |
| Chen, SD; Fan, GH; Qi, C; Wang, G; Zhou, HY | 1 |
| Horn, AS; Iversen, LL; Miller, RJ | 1 |
| Drucker-Colín, R; García-Hernández, F; Komisaruk, BR; Mendoza-Ramírez, JL; Pacheco-Cano, MT | 1 |
1 trial(s) available for bucladesine and Parkinson Disease
| Article | Year |
|---|---|
Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease.
Topics: Aged; Aged, 80 and over; Antigens, CD; Bucladesine; Carbon Isotopes; Cell Differentiation; Cells, Cultured; Cocaine; Dopamine Uptake Inhibitors; Female; Fetus; Flow Cytometry; Growth Substances; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neural Stem Cells; Neurons; Parkinson Disease; Pituitary Adenylate Cyclase-Activating Polypeptide; Positron-Emission Tomography; Retinal Pigment Epithelium; Severity of Illness Index; Time Factors; Treatment Outcome; Tretinoin | 2012 |
5 other study(ies) available for bucladesine and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective effects of a brain permeant 6-aminoquinoxaline derivative in cell culture conditions that model the loss of dopaminergic neurons in Parkinson disease.
Topics: Animals; Brain; Cell Culture Techniques; Cells, Cultured; Dopaminergic Neurons; Male; Mice, Inbred C57BL; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Quantitative Structure-Activity Relationship; Quinoxalines; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2015 |
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Female; Male; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Quinoxalines; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |
PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone.
Topics: Animals; Bucladesine; Caspase 3; Caspases; Cell Differentiation; Cell Survival; Colforsin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Intracellular Membranes; Isoquinolines; MAP Kinase Signaling System; Membrane Potentials; Mitochondria; Nerve Growth Factors; Neurons; Neuropeptides; Neurosecretory Systems; Neurotransmitter Agents; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; PC12 Cells; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Rats; Rotenone; Signal Transduction; Sulfonamides | 2005 |
Actions of dopaminergic agonists on cyclic AMP production in rat brain homogenates.
Topics: Animals; Antiparkinson Agents; Apomorphine; Aporphines; Bucladesine; Corpus Striatum; Cyclic AMP; Dopamine; Isoquinolines; Male; Naphthalenes; Parkinson Disease; Piribedil; Rats; Receptors, Drug; Tranquilizing Agents | 1975 |
Possible mechanisms of action of adrenal transplants in Parkinson's disease.
Topics: Adrenal Medulla; Aging; Animals; Apomorphine; Brain Tissue Transplantation; Bucladesine; Caudate Nucleus; Cerebral Ventricles; Dominance, Cerebral; Dopamine; Fetal Tissue Transplantation; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Pain; Parkinson Disease; Rats; Rats, Inbred Strains; Sensory Thresholds; Substantia Nigra; Transplantation, Heterotopic | 1990 |